Emergent Biosolutions (NYSE:EBS) had its price objective hoisted by research analysts at Chardan Capital from $47.00 to $53.00 in a research note issued to investors on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Chardan Capital’s price target would suggest a potential upside of 6.36% from the company’s previous close.

Several other research analysts also recently issued reports on EBS. Wells Fargo & Co restated an “outperform” rating and set a $43.00 price objective (up previously from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. Zacks Investment Research downgraded shares of Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 11th.

Shares of Emergent Biosolutions (EBS) traded up $1.01 on Tuesday, reaching $49.83. 350,700 shares of the company traded hands, compared to its average volume of 339,291. The company has a market cap of $2,050.00, a P/E ratio of 31.14, a PEG ratio of 1.01 and a beta of 1.29. Emergent Biosolutions has a 12-month low of $27.94 and a 12-month high of $50.14. The company has a quick ratio of 6.46, a current ratio of 7.37 and a debt-to-equity ratio of 0.38.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The company had revenue of $149.43 million for the quarter, compared to the consensus estimate of $124.55 million. During the same quarter in the previous year, the firm posted $0.56 EPS. The business’s revenue was up 4.6% compared to the same quarter last year. equities research analysts forecast that Emergent Biosolutions will post 1.66 EPS for the current year.

In other news, CEO Daniel Abdun-Nabi sold 31,508 shares of the business’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $42.77, for a total transaction of $1,347,597.16. Following the transaction, the chief executive officer now owns 215,642 shares in the company, valued at approximately $9,223,008.34. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director George A. Joulwan sold 14,251 shares of the business’s stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $41.24, for a total transaction of $587,711.24. Following the transaction, the director now owns 34,323 shares in the company, valued at approximately $1,415,480.52. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 206,329 shares of company stock worth $8,892,362. Insiders own 16.50% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its stake in Emergent Biosolutions by 0.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,224,198 shares of the biopharmaceutical company’s stock valued at $89,968,000 after acquiring an additional 18,486 shares during the period. Acadian Asset Management LLC increased its stake in Emergent Biosolutions by 6.2% in the fourth quarter. Acadian Asset Management LLC now owns 1,445,412 shares of the biopharmaceutical company’s stock valued at $67,165,000 after acquiring an additional 84,713 shares during the period. Royal Bank of Canada increased its stake in Emergent Biosolutions by 2.1% in the second quarter. Royal Bank of Canada now owns 958,568 shares of the biopharmaceutical company’s stock valued at $32,505,000 after acquiring an additional 19,833 shares during the period. Northern Trust Corp increased its stake in Emergent Biosolutions by 47.2% in the second quarter. Northern Trust Corp now owns 906,731 shares of the biopharmaceutical company’s stock valued at $30,747,000 after acquiring an additional 290,863 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Emergent Biosolutions by 16.7% in the second quarter. Renaissance Technologies LLC now owns 820,411 shares of the biopharmaceutical company’s stock valued at $27,820,000 after acquiring an additional 117,700 shares during the period. Institutional investors own 88.44% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/18/emergent-biosolutions-ebs-pt-raised-to-53-00-at-chardan-capital.html.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.